Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…
Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment…
Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome Equal Partnership with AFT Pharmaceuticals for Development of a…
Carbios_RDD_2022_MOCKUP_VEN 1 CARBIOS Sustainability Report 2022 PRESS RELEASE CARBIOS publishes its second sustainability report and confirms its ambitions to accelerate…
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the…
MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing…
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class…
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure – Representing the Highest Value…
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity…
WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage biopharmaceutical company focused on the…